Dynamic Quantitative Intravital Imaging of Glioblastoma Progression Reveals a Lack of Correlation between Tumor Growth and Blood Vessel Density

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Ricard, Clément ^a,b   Stanchi, Fabio ^a,c   Rodriguez, Thieric ^a   Amoureux, Marie Claude ^a,b   Rougon, Geneviève ^a,b   Debarbieux, Franck ^a,b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Aix Marseille University   (France)

^c VIB3 Vesalius Onderzoekscentrum KU ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL DENSITY; CONTROLLED STUDY; CORRELATIONAL STUDY; GLIOBLASTOMA; MALE; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; QUANTITATIVE ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MICE; MICE, NUDE; RECEPTORS, CXCR4; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884196348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072655     Document Type: Article

References (48)

1. Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, et al. (2009) Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 57: 1306-1315.
2. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, et al. (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17: 6192-6205.
3. Folkman J, (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, et al. (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622.
5. Chamberlain MC, (2011) Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5: 117-129.
6. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
7. Plate KH, Breier G, Weich HA, Risau W, (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
8. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848.
9. Bergers G, Hanahan D, (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
10. Chi AS, Norden AD, Wen PY, (2009) Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6: 513-526.
11. Norden AD, Drappatz J, Wen PY, (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20: 652-661.
12. Fink J, Born D, Chamberlain MC, (2011) Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol 12: 240-252.
13. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, et al. (2010) Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12: 466-472.
14. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, et al. (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9: 444.
15. Zhang L, Lapierre A, Roy B, Lim M, Zhu J, et al. (2012) Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window. J Vis Exp pp. 4201-4205.
16. Zhang L, Lapierre A, Roy B, Lim M, Zhu J, et al. (2012) Imaging glioma initiation in vivo through a polished and reinforced thin-skull cranial window. J Vis Exp.
17. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, et al. (2011) Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 71: 19-28.
18. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, et al. (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100: 13513-13518.
19. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139: 891-906.
20. Ulrich TA, de Juan Pardo EM, Kumar S, (2009) The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 69: 4167-4174.
21. Mackenzie F, Ruhrberg C, (2012) Diverse roles for VEGF-A in the nervous system. Development 139: 1371-1380.
22. Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, et al. (2012) Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells 30: 1831-1841.
23. Shojaei F, Ferrara N, (2008) Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 11: 219-230.
24. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, et al. (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14: 1379-1392.
25. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17: 2074-2080.
26. Schuss P, Ulrich CT, Harter PN, Tews DS, Seifert V, et al. (2011) Gliosarcoma with bone infiltration and extracranial growth: case report and review of literature. J Neurooncol 103: 765-770.
27. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, et al. (2008) The role of myosin II in glioma invasion of the brain. Mol Biol Cell 19: 3357-3368.
28. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG, (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36: 1046-1069.
29. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, et al. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27: 2542-2552.
30. Crawford Y, Ferrara N, (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 30: 624-630.
31. Hardee ME, Zagzag D, (2012) Mechanisms of glioma-associated neovascularization. Am J Pathol 181: 1126-1141.
32. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22: 21-35.
33. Koppenol WH, Bounds PL, Dang CV, (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337.
34. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, et al. (2010) Glial and neuronal control of brain blood flow. Nature 468: 232-243.
35. Brodbelt A, Stoodley M, (2007) CSF pathways: a review. Br J Neurosurg 21: 510-520.
36. Hochwald GM, Magee J, Ferguson V, (1985) Cerebrospinal fluid glucose: turnover and metabolism. J Neurochem 44: 1832-1837.
37. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
38. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, et al. (2006) Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 103: 16466-16471.
39. Du R, Lu KV, Petritsch C, Liu P, Ganss R, et al. (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220.
40. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, et al. (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68: 7342-7351.
41. Ribatti D, Crivellato E, Vacca A, (2012) Inflammation and antiangiogenesis in cancer. Curr Med Chem 19: 955-960.
42. Pollard JW, (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84: 623-630.
43. Siveen KS, Kuttan G, (2009) Role of macrophages in tumour progression. Immunol Lett 123: 97-102.
44. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, et al. (2009) The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115: 2031-2040.
45. Liu BY, Soloviev I, Chang P, Lee J, Huang X, et al. (2010) Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS One 5: e8611.
46. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, et al. (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100: 1111-1119.
47. Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, et al. (2012) Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol 227: 17-28.
48. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P, (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71: 7463-7470.